iX Biopharma (SGX:42C) Change In Receivables : S$-0.13 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma Change In Receivables?

iX Biopharma's change in receivables for the quarter that ended in Dec. 2023 was S$0.31 Mil. It means iX Biopharma's Accounts Receivable declined by S$0.31 Mil from Jun. 2023 to Dec. 2023 .

iX Biopharma's change in receivables for the fiscal year that ended in Jun. 2023 was S$-0.85 Mil. It means iX Biopharma's Accounts Receivable increased by S$0.85 Mil from Jun. 2022 to Jun. 2023 .

iX Biopharma's Accounts Receivable for the quarter that ended in Dec. 2023 was S$2.40 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. iX Biopharma's Days Sales Outstanding for the six months ended in Dec. 2023 was 164.13.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. iX Biopharma's liquidation value for the six months ended in Dec. 2023 was S$-2.26 Mil.

iX Biopharma Change In Receivables Historical Data

The historical data trend for iX Biopharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma Change In Receivables Chart

iX Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Receivables

Get a 7-Day Free Trial

-0.03

-0.23

0.02

-0.23

-0.85

iX Biopharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-1.45	1.22	-0.42	-0.43	0.31

iX Biopharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$-0.13 Mil.

iX Biopharma (SGX:42C) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

iX Biopharma's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.403	/	2.672	*	91
=	164.13

2. In Ben Graham's calculation of liquidation value, iX Biopharma's accounts receivable are only considered to be worth 75% of book value:

iX Biopharma's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	6.093	-	10.652	+	0.75 * 2.403	+	0.5 * 0.999
=	-2.26

iX Biopharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of iX Biopharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma (SGX:42C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma (SGX:42C) Headlines

No Headlines